News

Session at the 2023 American Psychiatric Association Annual Meeting shares insights on REMS for psychiatric medications.

Forgetting something?

Experts preview their upcoming presentation on women in psychiatry at the 2023 APA Annual Meeting.

A look at the theme for the 2023 American Psychiatric Association Annual Meeting.

Psychiatric Times’ climate editor previews the climate events at this year’s American Psychiatric Association Annual Meeting.

We mourn these psychiatrist leaders…

Check out our board members at these sessions at the 2023 APA Annual Meeting!

"CT-R emphasizes the importance of hope while taking it a step further, turning hope into meaningful action and internalizing what success says about a person’s identity, strength, and ability to navigate future challenges."

Want to connect with our Editor in Chief?

Let us know if you're attending!

"My attitude toward The Sixth Sense shifted when I realized that I had been treating a patient whose death date was set before our appointments began..."

Do we need a dialectical approach to psychiatry?

Deutetrabenazine extended-release tablets are now available.

"I have worked for organizations that treated health care clinicians like they were widget makers in factories."

What do the United States and borderline personality disorder have in common?

A psychiatrist reflects on the death of Jordan Neely, only a couple of weeks after his murder...

In honor of Mother's Day...

From the relationship between social media and self-diagnosis to the FDA approval of the first treatment for agitation associated with Alzheimer disease dementia, here are highlights from the week in Psychiatric Times.

"It is essential to have an aggressive path forward to increase public awareness of mental health and illness, education on early intervention and treatment access, and continued destigmatization of mental illness."

Coming out of your shell?

Individuals with schizophrenia have experienced an increase in psychiatric, medical, and treatment risks because of the COVID-19 pandemic.

Here are some things to check out in the city while you're in town...

It’s time for psychiatry to address the crisis at the border.

What movies are you watching this weekend?

Pain is escalating…

Brexpiprazole has been approved by the US Food and Drug Administration for the treatment of agitation associated with Alzheimer disease dementia.

Psychiatric Times® salutes our armed forces and remembers those who have fallen during service.

See you in San Francisco!

Study investigates connections between rTMS and factors including depression and cognitive performance.